<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.104067</article-id><article-id pub-id-type="publisher-id">TCM-43754</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210400000_69792742.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于网络药理学和加权基因共表达网络探析苓荷颗粒治疗代谢相关脂肪性肝病的潜在靶点和作用机制
  Integrating Network Pharmacology and Weighted Gene Co-Expression Network Analysis to Explore the Potential Targets and Mechanism of Linghe Granules in the Treatment of Metabolism Related Fatty Liver Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陆</surname><given-names>奕宇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>如棉</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>超群</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>章</surname><given-names>亭</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>龙</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>群</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蔡</surname><given-names>虹</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>华</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>上海中医药大学曙光医院肝病研究所，上海</addr-line></aff><aff id="aff2"><addr-line>上海中医药大学交叉科学研究院，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff3"><addr-line>厦门市中医院，福建 厦门</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>06</month><year>2021</year></pub-date><volume>10</volume><issue>04</issue><fpage>491</fpage><lpage>505</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨名老中医经验方苓荷颗粒治疗代谢相关脂肪性肝病(MAFLD)的潜在靶点和作用机制。方法：通过TCMSP数据库检索出苓荷颗粒所含主要的化学成分；通过TCMID，TCMSP，TCM-PTD，NSTI，SymMap数据库查出中药各成分作用靶标基因；检索Gene Cards，OMIM获得MAFLD相关基因靶点。将获得的苓荷颗粒作用靶点与MAFLD疾病靶点共同输入String数据库，构建药物作用靶点–疾病靶点PPI网络并进行分析。通过核心靶基因筛选及功能富集，最终构建中药–成分–直接靶点–间接靶点-pathway网络。同时，运用GEO数据库下载MAFLD患者RNA-seq高通量测序数据，并进行加权基因共表达网络分析(WGCNA)。结果：构建中药–成分–直接靶点–间接靶点-pathway整体网络，并获得36个潜在活性成分，28个直接靶点。发现TNF信号通路，MAPK信号通路，代谢相关肝病通路等相关通路的关键靶点基因涉及苓荷颗粒作用机制。结合WGCNA分析，找到GGT1，E2F1，LMNA，CDKN1A和IGFBP1 5个基因可能与MAFLD的发生发展密切相关。结论：苓荷颗粒通过TNF信号通路，MAPK信号通路，以及非酒精性肝病相关等生物过程发挥治疗MAFLD的作用；而GGT1、E2F1、LMNA、CDKN1A和IGFBP1是苓荷颗粒治疗MAFLD的潜在靶点。
  Objective: To explore the potential target and mechanism of Linghe granules in the treatment of metabolic associated fatty liver disease (MAFLD). Methods: The main chemical components of Linghe granules were retrieved by TCMSP database. The target genes of each component were identified by TCMID, TCMSP, TCM-PTD, NSTI, and symMap database. The database Genecards and OMIM were used to obtain the MAFLD related target genes. The targets of Linghe granules and MAFLD related targets were input into the String database to construct PPI network. After network analysis, core target genes were selected, of which functional enrichment analysis was performed. Based on the precious results, Linghe granules-component-direct target-indirect target-pathway network was constructed. Meanwhile, the high-throughput RNA-seq sequencing data of MAFLD patients were downloaded from the GEO database and analyzed by weighted correlation network analysis (WGCNA). Results: Thirty-six potential active components and 28 direct targets were obtained. The enriched pathways of Linghe granules related target genes include TNF signaling pathway, MAPK signaling pathway, and nonalcoholic liver disease. Integrated with WGCNA analysis, five genes, GGT1, E2F1, LMNA, CDKN1A and IGFBP1, were found to be closely associated with the occurrence and development of MAFLD. Conclusion: TNF signaling pathway, MAPK signaling pathway, and non-alcoholic liver disease biological processes are related to Linghe granules treating MAFLD. GGT1, E2F1, LMNA, CDKN1A and IGFBP1, are potential targets of Linghe granules in the treatment of MAFLD.
 
</p></abstract><kwd-group><kwd>苓荷颗粒，代谢相关脂肪性肝病，网络药理学，加权基因共表达网络, Linghe Granules</kwd><kwd> Metabolic Associated Fatty Liver Disease</kwd><kwd> Network Pharmacology</kwd><kwd>Weighted Gene Co-Expression Network</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨名老中医经验方苓荷颗粒治疗代谢相关脂肪性肝病(MAFLD)的潜在靶点和作用机制。方法：通过TCMSP数据库检索出苓荷颗粒所含主要的化学成分；通过TCMID，TCMSP，TCM-PTD，NSTI，SymMap数据库查出中药各成分作用靶标基因；检索Gene Cards，OMIM获得MAFLD相关基因靶点。将获得的苓荷颗粒作用靶点与MAFLD疾病靶点共同输入String数据库，构建药物作用靶点–疾病靶点PPI网络并进行分析。通过核心靶基因筛选及功能富集，最终构建中药–成分–直接靶点–间接靶点-pathway网络。同时，运用GEO数据库下载MAFLD患者RNA-seq高通量测序数据，并进行加权基因共表达网络分析(WGCNA)。结果：构建中药–成分–直接靶点–间接靶点-pathway整体网络，并获得36个潜在活性成分，28个直接靶点。发现TNF信号通路，MAPK信号通路，代谢相关肝病通路等相关通路的关键靶点基因涉及苓荷颗粒作用机制。结合WGCNA分析，找到GGT1，E2F1，LMNA，CDKN1A和IGFBP1 5个基因可能与MAFLD的发生发展密切相关。结论：苓荷颗粒通过TNF信号通路，MAPK信号通路，以及非酒精性肝病相关等生物过程发挥治疗MAFLD的作用；而GGT1、E2F1、LMNA、CDKN1A和IGFBP1是苓荷颗粒治疗MAFLD的潜在靶点。</p></sec><sec id="s2"><title>关键词</title><p>苓荷颗粒，代谢相关脂肪性肝病，网络药理学，加权基因共表达网络</p></sec><sec id="s3"><title>Integrating Network Pharmacology and Weighted Gene Co-Expression Network Analysis to Explore the Potential Targets and Mechanism of Linghe Granules in the Treatment of Metabolism Related Fatty Liver Disease<sup> </sup></title><p>Yiyu Lu<sup>1</sup>, Rumian Zhang<sup>2</sup>, Chaoqun Zhao<sup>3</sup>, Ting Zhang<sup>2</sup>, Long Chen<sup>3</sup>, Qun Zhou<sup>3</sup>, Hong Cai<sup>2*</sup>, Hua Zhang<sup>3*</sup></p><p><sup>1</sup>Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai</p><p><sup>2</sup>Xiamen Traditional Chinese Medicine Hospital, Xiamen Fujian</p><p><sup>3</sup>Institute of Liver Disease, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai</p><p><img src="//html.hanspub.org/file/4-2270704x5_hanspub.png" /></p><p>Received: May 11<sup>th</sup>, 2021; accepted: Jul. 1<sup>st</sup>, 2021; published: Jul. 8<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/4-2270704x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the potential target and mechanism of Linghe granules in the treatment of metabolic associated fatty liver disease (MAFLD). Methods: The main chemical components of Linghe granules were retrieved by TCMSP database. The target genes of each component were identified by TCMID, TCMSP, TCM-PTD, NSTI, and symMap database. The database Genecards and OMIM were used to obtain the MAFLD related target genes. The targets of Linghe granules and MAFLD related targets were input into the String database to construct PPI network. After network analysis, core target genes were selected, of which functional enrichment analysis was performed. Based on the precious results, Linghe granules-component-direct target-indirect target-pathway network was constructed. Meanwhile, the high-throughput RNA-seq sequencing data of MAFLD patients were downloaded from the GEO database and analyzed by weighted correlation network analysis (WGCNA). Results: Thirty-six potential active components and 28 direct targets were obtained. The enriched pathways of Linghe granules related target genes include TNF signaling pathway, MAPK signaling pathway, and nonalcoholic liver disease. Integrated with WGCNA analysis, five genes, GGT1, E2F1, LMNA, CDKN1A and IGFBP1, were found to be closely associated with the occurrence and development of MAFLD. Conclusion: TNF signaling pathway, MAPK signaling pathway, and non-alcoholic liver disease biological processes are related to Linghe granules treating MAFLD. GGT1, E2F1, LMNA, CDKN1A and IGFBP1, are potential targets of Linghe granules in the treatment of MAFLD.</p><p>Keywords:Linghe Granules, Metabolic Associated Fatty Liver Disease, Network Pharmacology, Weighted Gene Co-Expression Network</p><disp-formula id="hanspub.43754-formula21"><graphic xlink:href="//html.hanspub.org/file/4-2270704x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-2270704x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-2270704x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>非酒精性脂肪性肝病(nonalcoholic fatty liver disease, NAFLD)是临床上常见的与代谢功能障碍相关的肝脏疾病，全球患病率高达25% [<xref ref-type="bibr" rid="hanspub.43754-ref1">1</xref>]。有研究报道，从2016年至2030年，中国NAFLD人口预计将增长29.1%，达到3.458亿；同时，继发于NAFLD的失代偿性肝硬化和肝脏相关死亡也将增加一倍以上 [<xref ref-type="bibr" rid="hanspub.43754-ref2">2</xref>]。此外，因NAFLD与代谢紊乱相关，且参与2型糖尿病和动脉粥样硬化的发病，是心脑血管疾病及代谢综合征相关恶性肿瘤的危险因素之一，故面对发病率的攀升和疾病危害的增加，于2020年将NAFLD重新定义并更名为代谢相关脂肪性肝病(metabolic associated fatty liver disease, MAFLD)。</p><p>目前，MAFLD已替代病毒性肝炎，成为全球发病率最高的慢性肝病 [<xref ref-type="bibr" rid="hanspub.43754-ref3">3</xref>]，MAFLD前期肝脏脂肪积聚虽然可逆，但常因其无临床症状而被忽略。发现时多已进入肝脏炎性病变期，而脂肪性肝炎(NASH)又可进一步发展为脂肪性肝纤维化、肝硬化及肝癌，一旦进展到肝硬化，则为不可逆病变，可出现腹水、上消化道出血、肝性脑病、感染、肝肾综合征等系列并发症，严重危害生命健康。针对肝脏脂肪积聚，现代医学尚无FDA批准的有效治疗药物，仅以改变生活方式、减轻体重或控制并发症为主要手段。存在治疗个体差异大、远期疗效差、难以规范实施等问题。中医将MAFLD归属“肝癖”、“肥气”、“积聚”等范畴，中医药防治本病具有明显的优势与特色。</p><p>苓荷颗粒是已故全国名老中医康良石教授临床治疗MAFLD的有效经验方 [<xref ref-type="bibr" rid="hanspub.43754-ref4">4</xref>]，由茯苓、净山楂、荷叶、佛手、决明子、丹参、陈皮、玉米须八味药组成，临床疗效显著 [<xref ref-type="bibr" rid="hanspub.43754-ref5">5</xref>]。但因缺少作用靶点、效应机制的深入研究，制约了其疗效的发挥和推广应用。基于此，本研究运用网络药理学和加权基因共表达网络算法，对苓荷颗粒的效应机制、药效物质基础和作用靶标进行了初步探索，以期为苓荷颗粒治疗MAFLD提供数据支撑与临床指导。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 苓荷颗粒化学活性成分检索和筛选</title><p>以各单味药的标准中药名称或拉丁文为检索词，通过TCMSP和TCMID等数据库检索苓荷颗粒组成药物的全部化学成分，构建苓荷颗粒成分数据集。参考口服利用度(Oral bioavailability, OB)和药物相似性(drug-likeness，DL)进行筛选。选取同时满足OB ≥ 30％，DL ≥ 0.18的成分作为潜在的活性成分，构建苓荷颗粒活性成分数据库。检索数据库：TCMID (http://www.megabionet.org/tcmid/)；TCMSP (https://tcmspw.com/tcmsp.php)；TCM-PTD (http://tcm.zju.edu.cn/ptd/)；NSTI (http://www.ncmi.cn/)；SymMap (http://www.symmap.org/)。</p></sec><sec id="s6_2"><title>2.2. MAFLD 疾病靶点的预测</title><p>通过数据库搜索关键词“Nonalcoholic fatty liverdisease”或“Non-alcoholic fatty liverdisease”，查找与MAFLD相关的基因，合并相关数据库，去除重复基因，获得MAFLD疾病–靶点。检索数据库：Gene Cards (https://www.genecards.org/)；OMIM (http://www.omim.org/)。</p></sec><sec id="s6_3"><title>2.3. 构建蛋白相互作用网络并计算网络拓扑参数</title><p>将相关基因导入STRING 在线数据库(https://string-db.org)，设定Organism为“Homo sapiens”，隐藏与关键节点网络无连接的节点，得到蛋白相互作用网络(Protein-Protein Interaction, PPI)。将导出的网络节点关联数据导入Cytoscape 3.8.2软件，计算网络拓扑参数degree，closeness centrality，clustering coefficient，topological coefficient和betweenness centrality，筛选关键基因。并构建药物–靶点–疾病网络。</p></sec><sec id="s6_4"><title>2.4. WGCNA分析MAFLD相关潜在靶点基因</title><p>GEO下载MAFLD相关数据GSE135251，用于加权基因共表达网络分析(Weighted correlation network analysis, WGCNA)，探寻与MAFLD发生发展相关的潜在靶点基因。此数据集包括216例不同肝纤维化阶段的MAFLD患者和10例正常人的冷冻肝活检样本的高通量RNA测序数据 [<xref ref-type="bibr" rid="hanspub.43754-ref6">6</xref>]。利用R语言的Deseq2包筛选差异基因，利用WGCNA包，构建MALFD加权共表达网络 [<xref ref-type="bibr" rid="hanspub.43754-ref7">7</xref>]。</p><p>为了使构建的网络接近真实生物网络状态的无尺度网络，首先，使用Soft Threshold选择合适的软阈值参数β。然后根据所确定的软阈值，转变邻接矩阵成为0~1之间的连续值，再以基因间皮尔逊相关系数构建邻接矩阵，转换为拓扑矩阵，基于拓扑重叠矩阵的差异性度量识别构建模块。临床指标包括MAFLD的疾病与否(Disease/Normal)、严重程度(control = 0, early = 1, moderate = 2)、活动度积分(NAFLD activity score, NAS = 0~8)，以及肝纤维化分期(Fibrosisstage: F0~F4)。以最小尺寸20为分割的基因树状图，建立平均连锁层次聚类，将上述临床信息与表达模式与其相类似的基因划分为一个模块，筛选最优模块。</p></sec><sec id="s6_5"><title>2.5. 核心靶点生物功能注释分析</title><p>利用R语言clusterProfiler包进行靶点基因的功能注释及通路分析。基于Gene Ontology数据库(http://www.geneontology.org)对基因进行GO注释，基于KEGG数据库(http://www.genome.jp/keg/)对差异基因进行pathway注释。利用Fisher精确检验和卡方检验，以P &lt; 0.05及FDR &lt; 0.05，|fold change| &gt; 2为标准，计算每个GO的显著性水平和误判率，筛选出目标基因富集的显著性GO。并分析目的基因参与的pathway，获得目标基因富集的显著性pathway。</p></sec><sec id="s6_6"><title>2.6. 统计学分析</title><p>进行差异基因表达分析，方差齐的多样本间进行单因素方差分析(one-way ANOVA)，P &lt; 0.05为差异具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 苓荷颗粒潜在活性成分筛选</title><p>苓荷颗粒中8味药的成分共有8137个，共筛选到潜在活性成分134个。包括茯苓15个；陈皮5个；荷叶15个；玉米须12个；佛手5个；丹参65个；决明子14个；山楂3个(表1)。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Active ingredients of 8 herbs in Linghe granules (only 3 active ingredients are listed for each herb</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >MOL</th><th align="center" valign="middle" >Name</th><th align="center" valign="middle" >MW</th><th align="center" valign="middle" >OB</th><th align="center" valign="middle" >DL</th></tr></thead><tr><td align="center" valign="middle" >Fu Ling</td><td align="center" valign="middle" >MOL000273</td><td align="center" valign="middle" >(2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-enoic acid</td><td align="center" valign="middle" >470.76</td><td align="center" valign="middle" >30.93</td><td align="center" valign="middle" >0.81</td></tr><tr><td align="center" valign="middle" >Fu Ling</td><td align="center" valign="middle" >MOL000275</td><td align="center" valign="middle" >trametenolic acid</td><td align="center" valign="middle" >456.78</td><td align="center" valign="middle" >38.71</td><td align="center" valign="middle" >0.8</td></tr><tr><td align="center" valign="middle" >Fu Ling</td><td align="center" valign="middle" >MOL000276</td><td align="center" valign="middle" >7,9(11)-dehydropachymic acid</td><td align="center" valign="middle" >526.83</td><td align="center" valign="middle" >35.11</td><td align="center" valign="middle" >0.81</td></tr><tr><td align="center" valign="middle" >Chen Pi</td><td align="center" valign="middle" >MOL004328</td><td align="center" valign="middle" >Naringenin</td><td align="center" valign="middle" >272.27</td><td align="center" valign="middle" >59.29</td><td align="center" valign="middle" >0.21</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >Chen Pi</th><th align="center" valign="middle" >MOL005100</th><th align="center" valign="middle" >5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman -4-one</th><th align="center" valign="middle" >302.3</th><th align="center" valign="middle" >47.74</th><th align="center" valign="middle" >0.27</th></tr></thead><tr><td align="center" valign="middle" >Chen Pi</td><td align="center" valign="middle" >MOL005815</td><td align="center" valign="middle" >Citromitin</td><td align="center" valign="middle" >404.45</td><td align="center" valign="middle" >86.9</td><td align="center" valign="middle" >0.51</td></tr><tr><td align="center" valign="middle" >He Ye</td><td align="center" valign="middle" >MOL000098</td><td align="center" valign="middle" >Quercetin</td><td align="center" valign="middle" >302.25</td><td align="center" valign="middle" >46.43</td><td align="center" valign="middle" >0.28</td></tr><tr><td align="center" valign="middle" >He Ye</td><td align="center" valign="middle" >MOL000354</td><td align="center" valign="middle" >Isorhamnetin</td><td align="center" valign="middle" >316.28</td><td align="center" valign="middle" >49.6</td><td align="center" valign="middle" >0.31</td></tr><tr><td align="center" valign="middle" >He Ye</td><td align="center" valign="middle" >MOL000359</td><td align="center" valign="middle" >Sitosterol</td><td align="center" valign="middle" >414.79</td><td align="center" valign="middle" >36.91</td><td align="center" valign="middle" >0.75</td></tr><tr><td align="center" valign="middle" >Yu Mi Xu</td><td align="center" valign="middle" >MOL013357</td><td align="center" valign="middle" >(3S,6R,8S,9S,10R,13R,14S,17R)-17- [(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,6-diol</td><td align="center" valign="middle" >430.79</td><td align="center" valign="middle" >34.37</td><td align="center" valign="middle" >0.78</td></tr><tr><td align="center" valign="middle" >Yu Mi Xu</td><td align="center" valign="middle" >MOL003044</td><td align="center" valign="middle" >Chryseriol</td><td align="center" valign="middle" >300.28</td><td align="center" valign="middle" >35.85</td><td align="center" valign="middle" >0.27</td></tr><tr><td align="center" valign="middle" >Yu Mi Xu</td><td align="center" valign="middle" >MOL010862</td><td align="center" valign="middle" >α-tocopheryl quinone</td><td align="center" valign="middle" >446.79</td><td align="center" valign="middle" >35.91</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Fo Shou</td><td align="center" valign="middle" >MOL001323</td><td align="center" valign="middle" >Sitosterol alpha1</td><td align="center" valign="middle" >426.8</td><td align="center" valign="middle" >43.28</td><td align="center" valign="middle" >0.78</td></tr><tr><td align="center" valign="middle" >Fo Shou</td><td align="center" valign="middle" >MOL013253</td><td align="center" valign="middle" >5,2',5'-Trihydroxy-6,7,8-trimethoxyflavone</td><td align="center" valign="middle" >376.34</td><td align="center" valign="middle" >37.49</td><td align="center" valign="middle" >0.43</td></tr><tr><td align="center" valign="middle" >Fo Shou</td><td align="center" valign="middle" >MOL001506</td><td align="center" valign="middle" >Supraene</td><td align="center" valign="middle" >410.8</td><td align="center" valign="middle" >33.55</td><td align="center" valign="middle" >0.42</td></tr><tr><td align="center" valign="middle" >Dan Shen</td><td align="center" valign="middle" >MOL001601</td><td align="center" valign="middle" >1,2,5,6-tetrahydrotanshinone</td><td align="center" valign="middle" >280.34</td><td align="center" valign="middle" >38.75</td><td align="center" valign="middle" >0.36</td></tr><tr><td align="center" valign="middle" >Dan Shen</td><td align="center" valign="middle" >MOL001659</td><td align="center" valign="middle" >Poriferasterol</td><td align="center" valign="middle" >412.77</td><td align="center" valign="middle" >43.83</td><td align="center" valign="middle" >0.76</td></tr><tr><td align="center" valign="middle" >Dan Shen</td><td align="center" valign="middle" >MOL001771</td><td align="center" valign="middle" >poriferast-5-en-3beta-ol</td><td align="center" valign="middle" >414.79</td><td align="center" valign="middle" >36.91</td><td align="center" valign="middle" >0.75</td></tr><tr><td align="center" valign="middle" >Jue Ming Zi</td><td align="center" valign="middle" >MOL006486</td><td align="center" valign="middle" >Obtusin</td><td align="center" valign="middle" >344.34</td><td align="center" valign="middle" >31.24</td><td align="center" valign="middle" >0.4</td></tr><tr><td align="center" valign="middle" >Jue Ming Zi</td><td align="center" valign="middle" >MOL006472</td><td align="center" valign="middle" >Aurantio-obtusin</td><td align="center" valign="middle" >330.31</td><td align="center" valign="middle" >31.55</td><td align="center" valign="middle" >0.37</td></tr><tr><td align="center" valign="middle" >Jue Ming Zi</td><td align="center" valign="middle" >MOL005043</td><td align="center" valign="middle" >campest-5-en-3beta-ol</td><td align="center" valign="middle" >400.76</td><td align="center" valign="middle" >37.58</td><td align="center" valign="middle" >0.71</td></tr><tr><td align="center" valign="middle" >Shan Zha</td><td align="center" valign="middle" >MOL005384</td><td align="center" valign="middle" >Suchilactone</td><td align="center" valign="middle" >368.41</td><td align="center" valign="middle" >57.52</td><td align="center" valign="middle" >0.56</td></tr><tr><td align="center" valign="middle" >Shan Zha</td><td align="center" valign="middle" >MOL000073</td><td align="center" valign="middle" >Epicatechin</td><td align="center" valign="middle" >290.29</td><td align="center" valign="middle" >48.96</td><td align="center" valign="middle" >0.24</td></tr><tr><td align="center" valign="middle" >Shan Zha</td><td align="center" valign="middle" >MOL001645</td><td align="center" valign="middle" >linoleyl acetate</td><td align="center" valign="middle" >308.56</td><td align="center" valign="middle" >42.1</td><td align="center" valign="middle" >0.2</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 苓荷颗粒中8味药活性成分(每味药只列出3个活性成分)</p></sec><sec id="s7_2"><title>3.2. 苓荷颗粒–靶点构建</title><p>基于TCMID数据库中现存所有的中药成分–靶点数据信息，输入前述134个苓荷颗粒潜在活性成分，寻找苓荷颗粒–靶点。共获得258个潜在靶点基因(图1)。</p></sec><sec id="s7_3"><title>3.3. MAFLD疾病靶点的预测</title><p>OMIM共检索获得MAFLD的238个靶点基因；Genecards共检索获得MAFLD的847个靶点基因；去除重复的，共获得1029个MAFLD的靶点基因。</p></sec><sec id="s7_4"><title>3.4. 苓荷颗粒作用靶点与MAFLD相互作用网络</title><p>将获得的258个苓荷颗粒作用靶点与1029个MAFLD疾病靶点共同输入STRING数据库，构建药物作用靶点–疾病靶点PPI网络。本实验中：degree = 37，closeness = 0.425256，clustering coefficient = 0.403129，topological coefficient = 0.145755 和betweenness = 0.000416。选取同时满足上述三个阈值的节点作为此网络的关键节点，共77个(表2)。</p><p>图1. 苓荷颗粒成分–靶点网络图(134个潜在活性成分及258个潜在靶点基因)</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> 77 key target gene</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >Target name</th><th align="center" valign="middle" >Gene name</th><th align="center" valign="middle" >Degree</th><th align="center" valign="middle" >Betweenness Centrality</th><th align="center" valign="middle" >Closeness Centrality</th><th align="center" valign="middle" >Clustering Coefficient</th><th align="center" valign="middle" >Topological Coefficient</th></tr></thead><tr><td align="center" valign="middle" >E2F1</td><td align="center" valign="middle" >E2F transcription factor 1</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >4.37E−04</td><td align="center" valign="middle" >0.448</td><td align="center" valign="middle" >0.494</td><td align="center" valign="middle" >0.149</td></tr><tr><td align="center" valign="middle" >FGF19</td><td align="center" valign="middle" >fibroblast growth factor 19</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >7.22E−04</td><td align="center" valign="middle" >0.459</td><td align="center" valign="middle" >0.430</td><td align="center" valign="middle" >0.160</td></tr><tr><td align="center" valign="middle" >GGT1</td><td align="center" valign="middle" >gamma-glutamyltransferase 1</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >1.70E−03</td><td align="center" valign="middle" >0.484</td><td align="center" valign="middle" >0.412</td><td align="center" valign="middle" >0.152</td></tr><tr><td align="center" valign="middle" >IL18</td><td align="center" valign="middle" >interleukin 18</td><td align="center" valign="middle" >107</td><td align="center" valign="middle" >7.84E−04</td><td align="center" valign="middle" >0.472</td><td align="center" valign="middle" >0.540</td><td align="center" valign="middle" >0.157</td></tr><tr><td align="center" valign="middle" >SLC2A1</td><td align="center" valign="middle" >solute carrier family 2 member 1</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >4.85E−04</td><td align="center" valign="middle" >0.479</td><td align="center" valign="middle" >0.512</td><td align="center" valign="middle" >0.165</td></tr><tr><td align="center" valign="middle" >TIMP1</td><td align="center" valign="middle" >TIMP metallopeptidase inhibitor 1</td><td align="center" valign="middle" >129</td><td align="center" valign="middle" >1.05E−03</td><td align="center" valign="middle" >0.489</td><td align="center" valign="middle" >0.477</td><td align="center" valign="middle" >0.151</td></tr><tr><td align="center" valign="middle" >TGFB1</td><td align="center" valign="middle" >transforming growth factor beta 1</td><td align="center" valign="middle" >122</td><td align="center" valign="middle" >1.04E−03</td><td align="center" valign="middle" >0.492</td><td align="center" valign="middle" >0.496</td><td align="center" valign="middle" >0.152</td></tr><tr><td align="center" valign="middle" >HGF</td><td align="center" valign="middle" >hepatocyte growth factor</td><td align="center" valign="middle" >121</td><td align="center" valign="middle" >1.35E−03</td><td align="center" valign="middle" >0.494</td><td align="center" valign="middle" >0.486</td><td align="center" valign="middle" >0.150</td></tr><tr><td align="center" valign="middle" >CD68</td><td align="center" valign="middle" >CD68 molecule</td><td align="center" valign="middle" >103</td><td align="center" valign="middle" >1.29E−03</td><td align="center" valign="middle" >0.480</td><td align="center" valign="middle" >0.485</td><td align="center" valign="middle" >0.147</td></tr><tr><td align="center" valign="middle" >TIMP2</td><td align="center" valign="middle" >TIMP metallopeptidase inhibitor 2</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >4.88E−04</td><td align="center" valign="middle" >0.463</td><td align="center" valign="middle" >0.569</td><td align="center" valign="middle" >0.173</td></tr><tr><td align="center" valign="middle" >NCF1</td><td align="center" valign="middle" >neutrophil cytosolic factor 1</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >6.08E−04</td><td align="center" valign="middle" >0.469</td><td align="center" valign="middle" >0.490</td><td align="center" valign="middle" >0.158</td></tr><tr><td align="center" valign="middle" >NOS2</td><td align="center" valign="middle" >nitric oxide synthase 2</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >1.67E−03</td><td align="center" valign="middle" >0.487</td><td align="center" valign="middle" >0.464</td><td align="center" valign="middle" >0.151</td></tr><tr><td align="center" valign="middle" >MMP3</td><td align="center" valign="middle" >matrix metallopeptidase 3</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >9.66E−04</td><td align="center" valign="middle" >0.474</td><td align="center" valign="middle" >0.528</td><td align="center" valign="middle" >0.164</td></tr><tr><td align="center" valign="middle" >LCN2</td><td align="center" valign="middle" >lipocalin 2</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >9.45E−04</td><td align="center" valign="middle" >0.455</td><td align="center" valign="middle" >0.415</td><td align="center" valign="middle" >0.152</td></tr><tr><td align="center" valign="middle" >VDR</td><td align="center" valign="middle" >vitamin D</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >6.19E−04</td><td align="center" valign="middle" >0.471</td><td align="center" valign="middle" >0.460</td><td align="center" valign="middle" >0.168</td></tr><tr><td align="center" valign="middle" >CYP19A1</td><td align="center" valign="middle" >cytochrome P450 family 19 subfamily A member 1</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >7.55E−04</td><td align="center" valign="middle" >0.466</td><td align="center" valign="middle" >0.449</td><td align="center" valign="middle" >0.164</td></tr><tr><td align="center" valign="middle" >SELE</td><td align="center" valign="middle" >selectin E</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >9.33E−04</td><td align="center" valign="middle" >0.457</td><td align="center" valign="middle" >0.622</td><td align="center" valign="middle" >0.178</td></tr><tr><td align="center" valign="middle" >F3</td><td align="center" valign="middle" >coagulation factor III, tissue factor</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >6.98E−04</td><td align="center" valign="middle" >0.455</td><td align="center" valign="middle" >0.531</td><td align="center" valign="middle" >0.171</td></tr><tr><td align="center" valign="middle" >CTGF</td><td align="center" valign="middle" >connective tissue growth factor</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >1.07E−03</td><td align="center" valign="middle" >0.475</td><td align="center" valign="middle" >0.550</td><td align="center" valign="middle" >0.166</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >CNR1</th><th align="center" valign="middle" >cannabinoid receptor 1</th><th align="center" valign="middle" >77</th><th align="center" valign="middle" >5.51E−04</th><th align="center" valign="middle" >0.455</th><th align="center" valign="middle" >0.501</th><th align="center" valign="middle" >0.154</th></tr></thead><tr><td align="center" valign="middle" >GPX7</td><td align="center" valign="middle" >glutathione peroxidase 7</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >6.92E−04</td><td align="center" valign="middle" >0.451</td><td align="center" valign="middle" >0.470</td><td align="center" valign="middle" >0.152</td></tr><tr><td align="center" valign="middle" >LEPR</td><td align="center" valign="middle" >leptin receptor</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >6.99E−04</td><td align="center" valign="middle" >0.455</td><td align="center" valign="middle" >0.448</td><td align="center" valign="middle" >0.158</td></tr><tr><td align="center" valign="middle" >LOX</td><td align="center" valign="middle" >lysyl oxidase</td><td align="center" valign="middle" >86</td><td align="center" valign="middle" >2.28E−03</td><td align="center" valign="middle" >0.476</td><td align="center" valign="middle" >0.470</td><td align="center" valign="middle" >0.159</td></tr><tr><td align="center" valign="middle" >EGR1</td><td align="center" valign="middle" >early growth response 1</td><td align="center" valign="middle" >106</td><td align="center" valign="middle" >6.39E−04</td><td align="center" valign="middle" >0.486</td><td align="center" valign="middle" >0.493</td><td align="center" valign="middle" >0.159</td></tr><tr><td align="center" valign="middle" >IRF1</td><td align="center" valign="middle" >interferon regulatory factor 1</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >6.78E−04</td><td align="center" valign="middle" >0.465</td><td align="center" valign="middle" >0.510</td><td align="center" valign="middle" >0.155</td></tr><tr><td align="center" valign="middle" >CDH2</td><td align="center" valign="middle" >cadherin 2</td><td align="center" valign="middle" >102</td><td align="center" valign="middle" >1.10E−03</td><td align="center" valign="middle" >0.484</td><td align="center" valign="middle" >0.463</td><td align="center" valign="middle" >0.150</td></tr><tr><td align="center" valign="middle" >GJA1</td><td align="center" valign="middle" >gap junction protein alpha 1</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >1.29E−03</td><td align="center" valign="middle" >0.468</td><td align="center" valign="middle" >0.450</td><td align="center" valign="middle" >0.168</td></tr><tr><td align="center" valign="middle" >TERT</td><td align="center" valign="middle" >telomerase reverse transcriptase</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >4.64E−04</td><td align="center" valign="middle" >0.482</td><td align="center" valign="middle" >0.493</td><td align="center" valign="middle" >0.157</td></tr><tr><td align="center" valign="middle" >PGR</td><td align="center" valign="middle" >progesterone receptor</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >8.33E−04</td><td align="center" valign="middle" >0.479</td><td align="center" valign="middle" >0.472</td><td align="center" valign="middle" >0.157</td></tr><tr><td align="center" valign="middle" >CASP9</td><td align="center" valign="middle" >caspase 9</td><td align="center" valign="middle" >106</td><td align="center" valign="middle" >7.39E−04</td><td align="center" valign="middle" >0.496</td><td align="center" valign="middle" >0.519</td><td align="center" valign="middle" >0.151</td></tr><tr><td align="center" valign="middle" >ESR2</td><td align="center" valign="middle" >estrogen receptor 2</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >5.79E−04</td><td align="center" valign="middle" >0.473</td><td align="center" valign="middle" >0.490</td><td align="center" valign="middle" >0.171</td></tr><tr><td align="center" valign="middle" >ALPL</td><td align="center" valign="middle" >alkaline phosphatase, liver/bone/kidney</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >8.03E−04</td><td align="center" valign="middle" >0.464</td><td align="center" valign="middle" >0.443</td><td align="center" valign="middle" >0.158</td></tr><tr><td align="center" valign="middle" >TLR9</td><td align="center" valign="middle" >toll like receptor 9</td><td align="center" valign="middle" >104</td><td align="center" valign="middle" >6.60E−04</td><td align="center" valign="middle" >0.484</td><td align="center" valign="middle" >0.534</td><td align="center" valign="middle" >0.152</td></tr><tr><td align="center" valign="middle" >BGLAP</td><td align="center" valign="middle" >bone gamma-carboxyglutamate protein</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >5.81E−04</td><td align="center" valign="middle" >0.474</td><td align="center" valign="middle" >0.489</td><td align="center" valign="middle" >0.160</td></tr><tr><td align="center" valign="middle" >RUNX2</td><td align="center" valign="middle" >runt related transcription factor 2</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >1.05E−03</td><td align="center" valign="middle" >0.487</td><td align="center" valign="middle" >0.459</td><td align="center" valign="middle" >0.150</td></tr><tr><td align="center" valign="middle" >IGF2</td><td align="center" valign="middle" >insulin like growth factor 2</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >1.28E−03</td><td align="center" valign="middle" >0.480</td><td align="center" valign="middle" >0.448</td><td align="center" valign="middle" >0.147</td></tr><tr><td align="center" valign="middle" >CDKN1A</td><td align="center" valign="middle" >cyclin dependent kinase inhibitor 1A</td><td align="center" valign="middle" >111</td><td align="center" valign="middle" >2.84E−03</td><td align="center" valign="middle" >0.492</td><td align="center" valign="middle" >0.474</td><td align="center" valign="middle" >0.148</td></tr><tr><td align="center" valign="middle" >ALOX5</td><td align="center" valign="middle" >arachidonate 5-lipoxygenase</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >7.80E−04</td><td align="center" valign="middle" >0.457</td><td align="center" valign="middle" >0.457</td><td align="center" valign="middle" >0.168</td></tr><tr><td align="center" valign="middle" >VIM</td><td align="center" valign="middle" >Vimentin</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >6.24E−04</td><td align="center" valign="middle" >0.460</td><td align="center" valign="middle" >0.412</td><td align="center" valign="middle" >0.158</td></tr><tr><td align="center" valign="middle" >MCL1</td><td align="center" valign="middle" >BCL2 family apoptosis regulator</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >8.43E−04</td><td align="center" valign="middle" >0.488</td><td align="center" valign="middle" >0.503</td><td align="center" valign="middle" >0.151</td></tr><tr><td align="center" valign="middle" >LMNA</td><td align="center" valign="middle" >lamin A/C</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >1.66E−03</td><td align="center" valign="middle" >0.481</td><td align="center" valign="middle" >0.430</td><td align="center" valign="middle" >0.159</td></tr><tr><td align="center" valign="middle" >ITGB3</td><td align="center" valign="middle" >integrin subunit beta 3</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >4.86E−04</td><td align="center" valign="middle" >0.457</td><td align="center" valign="middle" >0.430</td><td align="center" valign="middle" >0.160</td></tr><tr><td align="center" valign="middle" >IRF3</td><td align="center" valign="middle" >interferon regulatory factor 3</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >9.55E−04</td><td align="center" valign="middle" >0.468</td><td align="center" valign="middle" >0.458</td><td align="center" valign="middle" >0.151</td></tr><tr><td align="center" valign="middle" >PDGFRB</td><td align="center" valign="middle" >platelet derived growth factor receptor beta</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >1.11E−03</td><td align="center" valign="middle" >0.478</td><td align="center" valign="middle" >0.440</td><td align="center" valign="middle" >0.151</td></tr><tr><td align="center" valign="middle" >TGFBR1</td><td align="center" valign="middle" >transforming growth factor beta receptor 1</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >8.98E−04</td><td align="center" valign="middle" >0.469</td><td align="center" valign="middle" >0.436</td><td align="center" valign="middle" >0.153</td></tr><tr><td align="center" valign="middle" >CCR2</td><td align="center" valign="middle" >C-C motif chemokine receptor 2</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >5.35E−04</td><td align="center" valign="middle" >0.458</td><td align="center" valign="middle" >0.550</td><td align="center" valign="middle" >0.158</td></tr><tr><td align="center" valign="middle" >CCL5</td><td align="center" valign="middle" >C-C motif chemokine ligand 5</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >9.25E−04</td><td align="center" valign="middle" >0.477</td><td align="center" valign="middle" >0.489</td><td align="center" valign="middle" >0.149</td></tr><tr><td align="center" valign="middle" >NAMPT</td><td align="center" valign="middle" >nicotinamide phosphoribosyltransferase</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >1.41E−03</td><td align="center" valign="middle" >0.465</td><td align="center" valign="middle" >0.427</td><td align="center" valign="middle" >0.148</td></tr><tr><td align="center" valign="middle" >IGFBP1</td><td align="center" valign="middle" >insulin like growth factor binding protein 1</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >6.02E−04</td><td align="center" valign="middle" >0.455</td><td align="center" valign="middle" >0.437</td><td align="center" valign="middle" >0.152</td></tr><tr><td align="center" valign="middle" >CEBPB</td><td align="center" valign="middle" >CCAAT/enhancer binding protein beta</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >2.60E−03</td><td align="center" valign="middle" >0.476</td><td align="center" valign="middle" >0.425</td><td align="center" valign="middle" >0.151</td></tr><tr><td align="center" valign="middle" >SOCS3</td><td align="center" valign="middle" >suppressor of cytokine signaling 3</td><td align="center" valign="middle" >104</td><td align="center" valign="middle" >2.60E−03</td><td align="center" valign="middle" >0.484</td><td align="center" valign="middle" >0.433</td><td align="center" valign="middle" >0.149</td></tr><tr><td align="center" valign="middle" >SIRT6</td><td align="center" valign="middle" >sirtuin 6</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >1.27E−03</td><td align="center" valign="middle" >0.475</td><td align="center" valign="middle" >0.404</td><td align="center" valign="middle" >0.148</td></tr><tr><td align="center" valign="middle" >NLRP3</td><td align="center" valign="middle" >NLR family pyrin domain containing 3</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >8.08E−04</td><td align="center" valign="middle" >0.467</td><td align="center" valign="middle" >0.582</td><td align="center" valign="middle" >0.170</td></tr><tr><td align="center" valign="middle" >ADIPOR1</td><td align="center" valign="middle" >adiponectin receptor 1</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >2.15E−03</td><td align="center" valign="middle" >0.447</td><td align="center" valign="middle" >0.563</td><td align="center" valign="middle" >0.179</td></tr><tr><td align="center" valign="middle" >PTPN1</td><td align="center" valign="middle" >protein tyrosine phosphatase, non-receptor type 1</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >6.01E−04</td><td align="center" valign="middle" >0.474</td><td align="center" valign="middle" >0.518</td><td align="center" valign="middle" >0.171</td></tr></tbody></table></table-wrap><table-wrap id="2_3"><table><tbody><thead><tr><th align="center" valign="middle" >IGFBP3</th><th align="center" valign="middle" >insulin like growth factor binding protein 3</th><th align="center" valign="middle" >93</th><th align="center" valign="middle" >5.56E−04</th><th align="center" valign="middle" >0.473</th><th align="center" valign="middle" >0.454</th><th align="center" valign="middle" >0.155</th></tr></thead><tr><td align="center" valign="middle" >TNFSF11</td><td align="center" valign="middle" >tumor necrosis factor superfamily member 11</td><td align="center" valign="middle" >110</td><td align="center" valign="middle" >7.21E−04</td><td align="center" valign="middle" >0.482</td><td align="center" valign="middle" >0.474</td><td align="center" valign="middle" >0.153</td></tr><tr><td align="center" valign="middle" >DDIT3</td><td align="center" valign="middle" >DNA damage inducible transcript 3</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >4.52E−04</td><td align="center" valign="middle" >0.479</td><td align="center" valign="middle" >0.500</td><td align="center" valign="middle" >0.160</td></tr><tr><td align="center" valign="middle" >VTN</td><td align="center" valign="middle" >Vitronectin</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >4.90E−04</td><td align="center" valign="middle" >0.458</td><td align="center" valign="middle" >0.503</td><td align="center" valign="middle" >0.162</td></tr><tr><td align="center" valign="middle" >MET</td><td align="center" valign="middle" >MET proto-oncogene, receptor tyrosine kinase</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >3.31E−03</td><td align="center" valign="middle" >0.478</td><td align="center" valign="middle" >0.537</td><td align="center" valign="middle" >0.163</td></tr><tr><td align="center" valign="middle" >MYD88</td><td align="center" valign="middle" >myeloid differentiation primary response 88</td><td align="center" valign="middle" >102</td><td align="center" valign="middle" >1.22E−03</td><td align="center" valign="middle" >0.483</td><td align="center" valign="middle" >0.528</td><td align="center" valign="middle" >0.147</td></tr><tr><td align="center" valign="middle" >RAF1</td><td align="center" valign="middle" >Raf-1 proto-oncogene, serine/threonine kinase</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >5.64E−04</td><td align="center" valign="middle" >0.482</td><td align="center" valign="middle" >0.443</td><td align="center" valign="middle" >0.150</td></tr><tr><td align="center" valign="middle" >PLAU</td><td align="center" valign="middle" >plasminogen activator, urokinase</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >7.48E−04</td><td align="center" valign="middle" >0.475</td><td align="center" valign="middle" >0.477</td><td align="center" valign="middle" >0.160</td></tr><tr><td align="center" valign="middle" >AHR</td><td align="center" valign="middle" >aryl hydrocarbon receptor</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >9.65E−04</td><td align="center" valign="middle" >0.476</td><td align="center" valign="middle" >0.429</td><td align="center" valign="middle" >0.154</td></tr><tr><td align="center" valign="middle" >TNFRSF1A</td><td align="center" valign="middle" >TNF receptor superfamily member 1A</td><td align="center" valign="middle" >111</td><td align="center" valign="middle" >1.25E−03</td><td align="center" valign="middle" >0.488</td><td align="center" valign="middle" >0.496</td><td align="center" valign="middle" >0.148</td></tr><tr><td align="center" valign="middle" >BIRC3</td><td align="center" valign="middle" >baculoviral IAP repeat containing 3</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >2.09E−03</td><td align="center" valign="middle" >0.458</td><td align="center" valign="middle" >0.511</td><td align="center" valign="middle" >0.159</td></tr><tr><td align="center" valign="middle" >BIRC2</td><td align="center" valign="middle" >baculoviral IAP repeat containing 2</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >7.52E−04</td><td align="center" valign="middle" >0.462</td><td align="center" valign="middle" >0.446</td><td align="center" valign="middle" >0.147</td></tr><tr><td align="center" valign="middle" >XBP1</td><td align="center" valign="middle" >X-box binding protein 1</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >1.42E−03</td><td align="center" valign="middle" >0.472</td><td align="center" valign="middle" >0.475</td><td align="center" valign="middle" >0.158</td></tr><tr><td align="center" valign="middle" >ERBB3</td><td align="center" valign="middle" >erb-b2 receptor tyrosine kinase 3</td><td align="center" valign="middle" >58</td><td align="center" valign="middle" >4.37E−04</td><td align="center" valign="middle" >0.466</td><td align="center" valign="middle" >0.604</td><td align="center" valign="middle" >0.182</td></tr><tr><td align="center" valign="middle" >BIRC5</td><td align="center" valign="middle" >baculoviral IAP repeat containing 5</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >5.75E−04</td><td align="center" valign="middle" >0.445</td><td align="center" valign="middle" >0.514</td><td align="center" valign="middle" >0.154</td></tr><tr><td align="center" valign="middle" >CTSB</td><td align="center" valign="middle" >cathepsin B</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >5.43E−04</td><td align="center" valign="middle" >0.466</td><td align="center" valign="middle" >0.503</td><td align="center" valign="middle" >0.166</td></tr><tr><td align="center" valign="middle" >EPHA2</td><td align="center" valign="middle" >EPH receptor A2</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >4.29E−04</td><td align="center" valign="middle" >0.460</td><td align="center" valign="middle" >0.537</td><td align="center" valign="middle" >0.173</td></tr><tr><td align="center" valign="middle" >MAP3K5</td><td align="center" valign="middle" >mitogen-activated protein kinase kinasekinase 5</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >4.76E−04</td><td align="center" valign="middle" >0.473</td><td align="center" valign="middle" >0.492</td><td align="center" valign="middle" >0.158</td></tr><tr><td align="center" valign="middle" >ATF6</td><td align="center" valign="middle" >activating transcription factor 6</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >4.21E−04</td><td align="center" valign="middle" >0.461</td><td align="center" valign="middle" >0.511</td><td align="center" valign="middle" >0.165</td></tr><tr><td align="center" valign="middle" >MAPK9</td><td align="center" valign="middle" >mitogen-activated protein kinase 9</td><td align="center" valign="middle" >90</td><td align="center" valign="middle" >6.02E−04</td><td align="center" valign="middle" >0.484</td><td align="center" valign="middle" >0.498</td><td align="center" valign="middle" >0.159</td></tr><tr><td align="center" valign="middle" >TNFAIP3</td><td align="center" valign="middle" >TNF alpha induced protein 3</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >1.35E−03</td><td align="center" valign="middle" >0.446</td><td align="center" valign="middle" >0.486</td><td align="center" valign="middle" >0.146</td></tr><tr><td align="center" valign="middle" >TGFBR2</td><td align="center" valign="middle" >transforming growth factor beta receptor 2</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >4.78E−04</td><td align="center" valign="middle" >0.466</td><td align="center" valign="middle" >0.470</td><td align="center" valign="middle" >0.156</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 77个关键靶点基因</p></sec><sec id="s7_5"><title>3.5. 中药–成分–直接靶点–间接靶点-pathway网络构建</title><p>将苓荷颗粒258个潜在靶点基因与77个关键靶点基因进行交集，得到的交集中的28个基因视为直接靶点基因。其余49个基因为间接靶点基因(图2)。</p><p>图2. 苓荷颗粒258个潜在靶点基因与77个关键靶点基因交集分析</p><p>进一步将此中药–成分–靶点网络与2.4中苓荷颗粒作用靶点与MAFLD相互作用网络整合，获得中药–成分–直接靶点–间接靶点–pathway整体网络，包括36个潜在活性成分，28个直接靶点，49个间接靶点及部分关键基因通路(图3)。</p><p>图3. 中药–成分–直接靶点–间接靶点-pathway网络</p><p>对77个关键靶点基因进行生物功能注释，分析GO下的分子功能BP和KEGG pathway。发现77个关键靶点基因涉及TNF信号通路，MAPK信号通路，非酒精性肝病等通路(前15个term) (图4)。</p><p>图4. 77个关键靶点基因的GO和KEGG pathway功能分析</p></sec><sec id="s7_6"><title>3.6. WGCNA分析MAFLD相关潜在靶点基因</title><p>运用GEO下载的MAFLD数据集进行差异基因分析，找到差异基因2796个。将上述差异基因进行WGCNA分析。为使构建的网络更符合无标度网络的特性，软阈值设置为4 (图5(a))。基于加权算法进行层次聚类分析，根据设定的软阈值和临床指标聚类结果进行分割，得到不同的基因模块(图5(b)~(d))。根据软阈值 = 4，模块内基因数n ≥ 20，模块切割高度0.25的标准化，确定14个模块。这14个模块与MAFLD的疾病与否、严重程度活动度积分及肝纤维化分期相关性见图5(c)。greenyellow，salmon，blue和brown前四个模块(图5(c)绿色框)和MAFLD的疾病发展显著相关性(P &lt; 0.0001)。将这四个模块中的1213个基因和77个关键基因相对比，发现GGT1，E2F1，LMNA，CDKN1A和IGFBP15个重复出现的基因。因此，推测这5个基因可能参与MAFLD的发生发展，并且有可能成为苓荷颗粒治疗MAFLD的潜在靶点，从而选择它们进行下一步研究。</p><p>图5. WGCNA分析。(a) WGCNA分析中的尺度独立性和平均连通性分析；(b) 聚类树状图；(c) 14个基因模块和临床特征值的相关性分析热图；(d) 不同模块间相关性热图</p></sec><sec id="s7_7"><title>3.7. GGT1，E2F1，LMNA，CDKN1A和IGFBP1在数据集中的表达</title><p>对这5个基因在MAFLD患者中的表达情况进行分析，随着MAFLD的发展，GGT1，E2F1，LMNA，和CDKN1A的表达显著升高；而IGFBP1则相反，随着MAFLD的发展，其表达显著降低(图6)。</p><p>图6. GGT1，E2F1，LMNA，CDKN1A和IGFBP1在MAFLD不同阶段患者中的表达情况</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>MAFLD系过食油腻肥甘，湿浊内生，脾胃乃伤。食而不运，脂膏留积于肝，致疏泄不利，所引发的一系列病证。如叶天士在《临证指南医案》云：“湿从内生者，必其人膏粮酒醴过度”。康老总结MAFLD病因，主要责之湿邪内盛，运化失常。病机为痰湿瘀浊壅滞，三焦气机升降失职，最终导致肝脏脂肪过多难以输出而积聚。故苓荷颗粒组方以茯苓益脾调脏、利水渗湿；荷叶泻肝行气、散瘀利水，合而为君；臣以陈皮理气健脾、宣通五脏；佛手舒肝和胃、消痞除胀；山楂行结气、消食积、开郁化滞；丹参祛瘀生新、理气活血，共助君之用；佐以玉米须利尿泻浊，决明子清肝益肾、利水通便。诸药协同，升降有度，运化有序，则可使湿邪内除，精微传输及时，气机枢纽得利，机体复常 [<xref ref-type="bibr" rid="hanspub.43754-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.43754-ref9">9</xref>]。课题组前期初步临床观察证实，苓荷颗粒能显著改善MAFLD患者体重、腰围、肝脏脂肪变性定量(CAP值)等肥胖相关指标和肝脏脂肪变性。</p><p>然而，虽已有前期临床数据证实苓荷颗粒治疗MAFLD具有较好的疗效，但是对其确切的疗效机制及作用靶点仍知之甚少。传统研究中药作用机制的方法大多从研究单个或少数几个基因、通路或者中药中的单体成分入手，具有一定的盲目性、局部性，无法对疾病的发生发展机制进行全局探索，难以从整体观揭示中药治疗疾病的多成分、多靶点、多通路的特点。以整体性、系统性为特点的网络药理学，与中医药整体观念、辨证论治、方剂配伍等原则不谋而合。由网络药理学参与并主导的“多成分，多靶点”研究策略已获得多次成功 [<xref ref-type="bibr" rid="hanspub.43754-ref10">10</xref>]。本研究采用WGCNA联合网络药理学的方法，构建无尺度网络，将差异基因分为14个模块，从中挖掘得到4个与MAFLD发生发展密切相关的基因群，进一步通过与前述网络药理学靶点分析结果进行比对，发现GGT1，E2F1，LMNA，CDKN1A和IGFBP1可能是苓荷颗粒治疗MAFLD的潜在靶点。</p><p>GGT1 (gamma-glutamyl transpeptidase，γ谷氨酰基转移酶)，是一种细胞表面酶，裂解细胞外谷胱甘肽(glutathione, GSH)等，在保持细胞内谷胱甘肽水平中起着重要的作用 [<xref ref-type="bibr" rid="hanspub.43754-ref11">11</xref>]。临床将其作为肝损伤标志之一。研究发现人类血清中GGT1水平与肥胖以及代谢综合症 [<xref ref-type="bibr" rid="hanspub.43754-ref12">12</xref>] 相关。澳大利亚的一项队列研究 [<xref ref-type="bibr" rid="hanspub.43754-ref13">13</xref>] 显示，一组与GGT关联的SNP同时也与心血管疾病及2型糖尿病等代谢性疾病强相关。GGT1同时也被发现是泽泻治疗糖尿病大鼠 [<xref ref-type="bibr" rid="hanspub.43754-ref14">14</xref>] 以及黄芪和紫草提取物治疗MAFLD肝病小鼠肝脂肪变性的靶点 [<xref ref-type="bibr" rid="hanspub.43754-ref15">15</xref>]。</p><p>在MAFLD中，胆固醇在肝脏中的蓄积是早期事件。已有研究证明E2F1通过调节蛋白通过原蛋白转化酶枯草杆菌蛋白酶/kexin 9 (PCSK9)来维持胆固醇稳态 [<xref ref-type="bibr" rid="hanspub.43754-ref16">16</xref>]。同时，MAFLD中的脂质代谢重排有助于疾病发展，在由MAFLD发展成肝癌的过程中，代谢重排是标志。Gonzalez Romero等 [<xref ref-type="bibr" rid="hanspub.43754-ref17">17</xref>] 的最新一项研究显示，E2F1-E2F2-Cpt2通路轴线的激活提供了肝癌发生所需的富含脂质的环境，在接受高脂饮食和二乙基亚硝胺给药的小鼠中，MAFLD相关肝癌中E2F1和E2F2的表达增加。</p><p>LMNA编码的Lamin A/C是细胞核纤层的主要组成部分，直接或间接与染色质相互作用，在维持染色质结构、DNA复制、转录和细胞凋亡等方面发挥重要作用 [<xref ref-type="bibr" rid="hanspub.43754-ref18">18</xref>]。目前已有多个研究发现，LMNA基因的突变或多态性与多种代谢性疾病密切相关 [<xref ref-type="bibr" rid="hanspub.43754-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.43754-ref20">20</xref>]。</p><p>蛋白p21由CDKN1A编码。研究表明，CDKN1A变异与疾病进展的速度有关，比如，CDKN1A变体与特发性肺纤维化的快速发展有关 [<xref ref-type="bibr" rid="hanspub.43754-ref21">21</xref>]。CDKN1A可能在NAFLD的疾病进展中起类似作用 [<xref ref-type="bibr" rid="hanspub.43754-ref21">21</xref>]。Aravinthan等 [<xref ref-type="bibr" rid="hanspub.43754-ref22">22</xref>] 通过比较无纤维化和有纤维化的NAFLD患者，检验CDKN1A变异对肝纤维化的影响，研究发现CDKN1A(p21)的rs762623和纤维化密切相关。</p><p>胰岛素样生长因子结合蛋白1 (IGFBP-1)是六个IGFBP之一，它们结合并调节胰岛素样生长因子1 (IGF-1)的生物利用度 [<xref ref-type="bibr" rid="hanspub.43754-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.43754-ref24">24</xref>]。我们的结果显示IGFBP1的表达和其他4个基因不同，随着MAFLD的发展，其表达逐步降低(图6)，本结果和文献报道一致 [<xref ref-type="bibr" rid="hanspub.43754-ref25">25</xref>]。Stanley等 [<xref ref-type="bibr" rid="hanspub.43754-ref26">26</xref>] 的研究显示，具有较高脂肪变性和NAS活性评分的个体肝脏中的IGF1 mRNA显著降低。磷酸化的IGFBP-1可作为MAFLD中肝脂肪的非侵入性预测生物标志物 [<xref ref-type="bibr" rid="hanspub.43754-ref27">27</xref>]。</p><p>综上，本研究发现，苓荷颗粒作用相关的关键基因涉及TNF信号通路，MAPK信号通路，非酒精性肝病等通路。进一步结合WGCNA分析发现的GGT1，E2F1，LMNA，CDKN1A和IGFBP1和MAFLD的发生发展密切相关，为苓荷颗粒治疗MAFLD的潜在靶点。本研究结果可为未来进一步研究苓荷颗粒作用于MAFLD的实验研究及临床运用提供理论依据和实验依据。</p></sec><sec id="s9"><title>基金项目</title><p>上海市“科技创新行动计划”自然科学基金项目(20ZR1453700)；国家自然基金青年项目(81503478)；厦门市中医院项目(202101)。</p></sec><sec id="s10"><title>文章引用</title><p>陆奕宇,张如棉,赵超群,章 亭,陈 龙,周 群,蔡 虹,张 华. 基于网络药理学和加权基因共表达网络探析苓荷颗粒治疗代谢相关脂肪性肝病的潜在靶点和作用机制Integrating Network Pharmacology and Weighted Gene Co-Expression Network Analysis to Explore the Potential Targets and Mechanism of Linghe Granules in the Treatment of Metabolism Related Fatty Liver Disease[J]. 中医学, 2021, 10(04): 491-505. https://doi.org/10.12677/TCM.2021.104067</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43754-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., et al. (2019) Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 69, 2672-2682. 
&lt;br&gt;https://doi.org/10.1002/hep.30251</mixed-citation></ref><ref id="hanspub.43754-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Estes, C., Anstee, Q.M., Arias-Loste, M.T., Bantel, H., Bellentani, S., Caballeria, J., et al. (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030. Journal of Hepatology, 69, 896-904. &lt;br&gt;https://doi.org/10.1016/j.jhep.2018.05.036</mixed-citation></ref><ref id="hanspub.43754-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版) [J]. 中华肝脏病杂志, 2018, 26(3): 195-203.</mixed-citation></ref><ref id="hanspub.43754-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">章亭, 康旻睿, 张如棉, 康素琼, 吴剑华. 康良石教授治疗非酒精性脂肪肝经验[J]. 光明中医, 2013, 28(9): 1806-1807.</mixed-citation></ref><ref id="hanspub.43754-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">张如棉, 吴剑华, 康俊杰, 章亭, 于洪涛. 康氏系列方联合拉米夫定治疗慢性乙型肝炎的疗效初探[J]. 中西医结合肝病杂志, 2009, 19(5): 309-311.</mixed-citation></ref><ref id="hanspub.43754-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., et al. (2020) Transcriptomic Profiling across the Nonalcoholic Fatty Liver Disease Spectrum Reveals Gene Signatures for Steatohepatitis and Fibrosis. Science Translational Medicine, 12, Article No. eaba4448. &lt;br&gt;https://doi.org/10.1126/scitranslmed.aba4448</mixed-citation></ref><ref id="hanspub.43754-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Langfelder, P. and Horvath, S. (2008) WGCNA: An R Package for Weighted Gene Co-Expression Network Analysis. BMC Bioinformatics, 9, Article No. 559. &lt;br&gt;https://doi.org/10.1186/1471-2105-9-559</mixed-citation></ref><ref id="hanspub.43754-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">钟杰璋, 陈贻威, 潘家丽, 黄慧学. 中药治疗酒精性肝病的研究进展[J]. 世界中医药, 2018, 13(2): 504-507+512.</mixed-citation></ref><ref id="hanspub.43754-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">乐琦琦, 刘晏. 非酒精性脂肪肝的临床和药理研究进展[J]. 中成药. 2014, 36(2): 371-376.</mixed-citation></ref><ref id="hanspub.43754-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, R., Zhu, X., Bai, H. and Ning, K. (2019) Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment. Frontiers in Pharmacology, 10, Article No. 123. &lt;br&gt;https://doi.org/10.3389/fphar.2019.00123</mixed-citation></ref><ref id="hanspub.43754-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wickham, S., West, M.B., Cook, P.F. and Hanigan, M.H. (2011) Gamma-Glutamyl Compounds: Substrate Specificity of Gamma-Glutamyl Transpeptidase Enzymes. Analytical Biochemistry, 414, 208-214.  
&lt;br&gt;https://doi.org/10.1016/j.ab.2011.03.026</mixed-citation></ref><ref id="hanspub.43754-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Liu, C.F., Zhou, W.N. and Fang, N.Y. (2012) Gam-ma-Glutamyltransferase Levels and Risk of Metabolic Syndrome: A Meta-Analysis of Prospective Cohort Studies. International Journal of Clinical Practice, 66, 692-698.  
&lt;br&gt;https://doi.org/10.1111/j.1742-1241.2012.02959.x</mixed-citation></ref><ref id="hanspub.43754-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Middelberg, R.P., Benyamin, B., de Moor, M.H., Warrington, N.M., Gordon, S., Henders, A.K., et al. (2012) Loci Affecting Gamma-Glutamyl Transferase in Adults and Adolescents Show Age × SNP Interaction and Cardiometabolic Disease Associations. Human Molecular Genetics, 21, 446-455. &lt;br&gt;https://doi.org/10.1093/hmg/ddr478</mixed-citation></ref><ref id="hanspub.43754-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Xu, X., Li, L., Zhang, Y., Lu, X., Lin, W., Wu, S., et al. (2020) Hypolipidemic Effect of Alisma orientale (Sam.) Juzep on Gut Microecology and Liver Transcriptome in Diabetic Rats. PLoS ONE, 15, e0240616.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0240616</mixed-citation></ref><ref id="hanspub.43754-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Choi, D.J., Kim, S.C., Park, G.E., Choi, B.-R., Lee, D.Y., Lee, Y.-S., et al. (2020) Protective Effect of a Mixture of Astragalus membranaceus and Lithospermum erythrorhizon Extract against Hepatic Steatosis in High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Mice. Evidence-Based Complementary and Alternative Medicine, 2020, Article ID: 8370698. &lt;br&gt;https://doi.org/10.1155/2020/8370698</mixed-citation></ref><ref id="hanspub.43754-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lai, Q., Giralt, A., Le May, C., Zhang, L., Cariou, B., Denechaud, P.-D., et al. (2017) E2F1 Inhibits Circulating Cholesterol Clearance by Regulating Pcsk9 Expression in the Liver. JCI Insight, 2, e89729.  
&lt;br&gt;https://doi.org/10.1172/jci.insight.89729</mixed-citation></ref><ref id="hanspub.43754-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Gonzalez-Romero, F., Mestre, D., Aurrekoetxea, I., O’Rourke, C.J., Andersen, J.B., Woodhoo, A., et al. (2021) E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. Cancer Research, 81, 2874-2887. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-20-2052</mixed-citation></ref><ref id="hanspub.43754-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Dittmer, T. and Misteli, T. (2011) The Lamin Protein Family. Genome Biology, 12, Article No, 222.  
&lt;br&gt;https://doi.org/10.1186/gb-2011-12-5-222</mixed-citation></ref><ref id="hanspub.43754-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Desgrouas, C., Varlet, A.A., Dutour, A., Galant, D., Merono, F., Bonello-Palot, N., et al. (2020) Unraveling LMNA Mutations in Metabolic Syndrome: Cellular Phenotype and Clinical Pitfalls. Cells, 9, Article No. 310.  
&lt;br&gt;https://doi.org/10.3390/cells9020310</mixed-citation></ref><ref id="hanspub.43754-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">苏本利, 张晓青, 赵蔚, 赵海燕, 张萍, 吕申. 非糖尿病与糖尿患者群LMNA1908C/T基因多态性与血脂代谢紊乱的关系[J]. 中国临床康复, 2004, 8(9): 1690-1692.</mixed-citation></ref><ref id="hanspub.43754-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Korthagen, N.M., van Moorsel, C.H., Barlo, N.P., Kazemier, K.M., Ruven, H.J.T. and Grutters, J.C. (2012) Association between Variations in Cell Cycle Genes and Idiopathic Pulmonary Fibrosis. PLoS ONE, 7, e30442.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0030442</mixed-citation></ref><ref id="hanspub.43754-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Aravinthan, A., Mells, G., Allison, M., et al. (2014) Gene Polymorphisms of Cellular Senescence Marker p21 and Disease Progression in Non-Alcohol-Related Fatty Liver Disease. Cell Cycle, 13, 1489-1494.  
&lt;br&gt;https://doi.org/10.4161/cc.28471</mixed-citation></ref><ref id="hanspub.43754-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Firth, S.M. and Baxter, R.C. (2002) Cellular Actions of the Insulin-Like Growth Factor Binding Proteins. Endocrine Reviews, 23, 824-854. &lt;br&gt;https://doi.org/10.1210/er.2001-0033</mixed-citation></ref><ref id="hanspub.43754-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Adamek, A. and Kasprzak, A. (2018) Insulin-Like Growth Factor (IGF) System in Liver Diseases. International Journal of Molecular Sciences, 19, Article No. 1308. &lt;br&gt;https://doi.org/10.3390/ijms19051308</mixed-citation></ref><ref id="hanspub.43754-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Colak, Y., Senates, E., Ozturk, O., Yilmaz, Y., Zemheri, E., Yilmaz Enc, F., et al. (2012) Serum Concentrations of Human Insulin-Like Growth Factor-1 and Levels of Insulin-Like Growth Factor-Binding Protein-5 in Patients with Nonalcoholic Fatty Liver Disease: Association with Liver Histology. European Journal of Gastroenterology &amp; Hepatology, 24, 255-261.</mixed-citation></ref><ref id="hanspub.43754-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Stanley, T.L., Fourman, L.T., Zheng, I., McClure, C.M., Feldpausch, M.N., Torriani, M., et al. (2021) Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology &amp; Metabolism, 106, e520-e533. &lt;br&gt;https://doi.org/10.1210/clinem/dgaa792</mixed-citation></ref><ref id="hanspub.43754-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Petäjä, E.M., Zhou, Y., Havana, M., Hakkarainen, A., Lundbom, N., Ihalainen, J., et al. (2016) Phosphorylated IGFBP-1 as a Non-Invasive Predictor of Liver Fat in NAFLD. Scientific Reports, 6, Article No. 24740.  
&lt;br&gt;https://doi.org/10.1038/srep24740</mixed-citation></ref></ref-list></back></article>